TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03389477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
Study: NCT02678247

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Northwestern University Flexible Sub-Ischial Vacuum Socket
Description: NU-FlexSIV sockets have lower proximal trim lines, do not impinge on the pelvis, are highly flexible so as to allow better comfort during sitting and when muscles move within the socket during activity, and are held securely to the residual limb by suction from a vacuum pump and from compression exerted by the deliberately undersized liner and socket.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Northwestern University Flexible Sub-Ischial Vacuum Socket
Description: NU-FlexSIV sockets have lower proximal trim lines, do not impinge on the pelvis, are highly flexible so as to allow better comfort during sitting and when muscles move within the socket during activity, and are held securely to the residual limb by suction from a vacuum pump and from compression exerted by the deliberately undersized liner and socket.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ischial Containment Socket
Description: Ischial Containment (IC) sockets are more rigid and have a narrower medio-lateral dimension than anterior-posterior dimension. The socket encapsulates the ischium, ischial ramus and greater trochanter, limiting hip range of motion and comfort.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ischial Containment Socket
Description: Ischial Containment (IC) sockets are more rigid and have a narrower medio-lateral dimension than anterior-posterior dimension. The socket encapsulates the ischium, ischial ramus and greater trochanter, limiting hip range of motion and comfort.
Study: NCT03707197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Ten minutes of meditation per day for 8 weeks using a mobile application
Study: NCT00956748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprodex
Description: Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprodex and 2% NAC
Description: Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
Study: NCT02954965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reward
Description: Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are rewarding and pleasurable and to integrate these activities into their schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach
Description: Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are challenging, but important to their long-term goals and values, and to integrate these activities into their schedule.
Study: NCT01704638

Intervention type: DRUG
Group type: OTHER
Intervention: fluvoxamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine

Intervention type: DRUG
Group type: OTHER
Intervention: Digoxin
Study: NCT03389477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: -Cetuximab must not be administered as an IV push or bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: -Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: -Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: -Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: * Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy~* If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: * Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy~* If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: Baseline and post-treatment
Study: NCT01704638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study: NCT03322072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-Time Position Transponder Beacons
Description: The anchored lung tracking beacons are passive electromagnetic transponder beacons which are placed immediately adjacent to a lung tumor using a bronchoscope. Three beacons will be placed in the small airways of the lung adjacent to the target tumor (within 3 cm of the tumor). Each beacon measures 2 mm in diameter and 8 mm in length and consists of a miniature electrical circuit that is encapsulated in a biocompatible glass capsule. Each beacon has an affixed five-legged anchoring system which expands to 5mm diameter once deployed. The Calypso transponder beacon is placed endobronchially using the working channel of a bronchoscope. Navigational bronchoscopy can be used to pre-plan the optimal location for each beacon to be placed within the airways by using a pre-bronchoscopy CT scan.
Study: NCT02533570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04574167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
Study: NCT03316300

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NT-501
Description: Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.
Study: NCT01791036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
Study: NCT03389477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: Baseline and post-treatment
Study: NCT04126798

Intervention type: OTHER
Intervention: Behavioural
Description: Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks

Intervention type: OTHER
Intervention: Behavioural
Description: Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks

Intervention type: OTHER
Intervention: Behavioural
Description: Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks
Study: NCT04495218

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.
Study: NCT02678182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250 mg/m2/day, 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250 mg/m2/day, 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)
Description: IV treatment on days 1\&15 of 28 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6mg/kg on day 1 cycle every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 600mg PO twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: ramucirumab 8mg/kg IV day 1 and day 8
Study: NCT03600324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-REV
Description: For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-REV
Description: For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-REV
Description: For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-REV
Description: For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.
Study: NCT02206204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for selexipag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Study: NCT02700607

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Crystalloid
Description: crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous HES
Description: HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study: NCT01711554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02428062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodynamic target
Description: The anaesthesiologist is requested to maintain intraoperative mean arterial blood pressure of the patient within 10% of the baseline mean arterial blood pressure (recorded during the preoperative evaluation) of that patient. In order to reach this hemodynamic target the anesthesiologist can choose between one or more of the following four sub-interventions:~1. vasoconstrictor agents (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine)~2. intravenous fluids~3. patient's positioning~4. reduction of depth of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine 0.1-0.2 mg intravenous bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous fluids
Description: A crystalloid fluid bolus is given intravenously (5-10 ml/kg)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient's positioning
Description: The operating table is positioned so that the patient's head lies below the level of the patient's feet (Trendelenburg position) in order to increase venous return

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduction of depth of anesthesia
Description: The halogenated anesthetic vapor's inspiratory fraction is decreased in order to reduce the associated peripheral vasodilation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Ephedrine 5-25 mg intravenous bolus
Study: NCT02206204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin-matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin-matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin-matching placebo
Study: NCT00708422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005% (XALATAN®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
Study: NCT03196024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-focused intervention arm
Description: Family pairs including an individual family member at-risk for type 2 diabetes or CVD and a co-participating family member will be enrolled in the study. After completing baseline data they will be randomly selected to participate in one of the two study arms. For the family-focused arm, the family pair will attend 8 2-hour weekly educational sessions about type 2 diabetes and CVD risk reducing lifestyle behaviors. The sessions will be presented by community health workers (CHWs) in Spanish to groups of 5 to 6 family pairs. Following completion of the sessions, data will be collected from the family pairs. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the family pairs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual-focused intervention arm
Description: Family pairs including an individual family member at-risk for type 2 diabetes or CVD and co-participating family member will be enrolled in the study. After completing baseline data pairs will be randomly selected to participate in one of two interventions. For the individual-focused intervention, the at-risk individual will attend 8 weekly 2-hour education sessions on type 2 diabetes and CVD risk reducing lifestyle behaviors. Sessions will be presented by CHWs in Spanish to groups of 10 to 12 individuals. Following completion of sessions, data will be collected from the individuals. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the at-risk individuals and their co-participating family members.
Study: NCT06046027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accupressure band
Description: The accupressure band and wirst band will be place 20 minutes prior to induction of anaesthesia. The induction and maintenance of anaesthesia performed at the discretion of the supervising anaesthesiologist. The maintenance of anaesthesia was achieved by administering sevoflurane at a minimum alveolar concentration (MAC) range of 1 to 1.2. A fresh gas flow rate of 2 L/min comprising a 50:50 concentration mixture of oxygen and air were employed. The patients will be ventilated and maintain end-tidal carbon dioxide (ETCO2) levels within the range of 35-40mmHg. All patients were administered intravenous dexamethasone at a dosage of 0.1mg/kg as a conventional prophylaxis for postoperative nausea and vomiting (PONV) following the induction of anaesthesia. Additionally, intravenous morphine was administered at a dosage of 0.05mg/kg and suppositories containing paracetamol were given at a dosage of 30mg/kg for analgesic purposes. Patients will be extubated at the end of surgery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Accupressure band
Description: The accupressure band and wirst band will be place 20 minutes prior to induction of anaesthesia. The induction and maintenance of anaesthesia performed at the discretion of the supervising anaesthesiologist. The maintenance of anaesthesia was achieved by administering sevoflurane at a minimum alveolar concentration (MAC) range of 1 to 1.2. A fresh gas flow rate of 2 L/min comprising a 50:50 concentration mixture of oxygen and air were employed. The patients will be ventilated and maintain end-tidal carbon dioxide (ETCO2) levels within the range of 35-40mmHg. All patients were administered intravenous dexamethasone at a dosage of 0.1mg/kg as a conventional prophylaxis for postoperative nausea and vomiting (PONV) following the induction of anaesthesia. Additionally, intravenous morphine was administered at a dosage of 0.05mg/kg and suppositories containing paracetamol were given at a dosage of 30mg/kg for analgesic purposes. Patients will be extubated at the end of surgery
Study: NCT04331756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guiding Emergence From Anaesthesia With Tragus Pressure
Description: Use of tragus pressure in guiding patients from emergence from anaesthesia post-surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Guiding Emergence From Anaesthesia Without Tragus Pressure
Description: Usual clinical routine practice in guiding patients from emergence from anaesthesia post-surgery
Study: NCT01659567

Intervention type: DRUG
Intervention: Pegylated Interferon Alfa-2a
Description: Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
Study: NCT05140096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Modify as Participants will receive a single oral dose of 100 mg (1 X 100 mg capsule) acalabrutinib either on Day 1 of Period 1 (Treatment A) and Day 1 of Period 2 (Treatment B) or Day 5 of Period 2 (Treatment C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Modify as Participants will receive a single oral dose of 100 mg (1 X 100 mg capsule) acalabrutinib either on Day 1 of Period 1 (Treatment A) and Day 1 of Period 2 (Treatment B) or Day 5 of Period 2 (Treatment C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Participants will receive 400 mg fluconazole (2 × 200 mg tablets) on Day 1 Period 2 (Treatment B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Participant will receive oral dose of 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) three times daily on Day 1 and 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) once daily on Days 2 to 5 in Period 2 (Treatment C).
Study: NCT03066999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy
Description: Patients will assign to either Group Cystoscopy (catheter placement via cystoscopy)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DirectVision
Description: Patients will assign to either Group DirectVision (catheter placement via DirectVision)